Neurology News

The FDA granted orphan drug exclusivity for JZP258, an oral low-sodium oxybate solution for the treatment of idiopathic hypersomnia in adults, according to Jazz Pharmaceuticals.

An integrated ambulatory care model that had infusion capacity for pediatric refractory headache appeared feasible and beneficial for these patients, according to a quality improvement study.

Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.

Excessive daytime sleepiness, nonrestorative sleep and sleep behaviors all play a significant role in sleep health, according to results of a network analysis of sleep variables published in Sleep Epidemiology.

Healio Neurology’s most-viewed stories from 2021 highlight developments surrounding Aduhelm, the benefits of flavonoid on cognitive function and neurologic symptoms in COVID-19.

Physicians interested in estate or asset protection planning inevitably inquire about the use of trusts. Certainly, trusts can play significant roles in many physicians’ estate and/or asset protection planning.

The FDA has accepted a new drug application, or NDA, for a combination of sodium phenylbutyrate and taurursodiol intended to treat ALS, Amylyx Pharmaceuticals Inc. announced in a press release.

Individuals with pediatric-onset MS may exhibit disturbances in their gut microbiome, according to study results published in Neurology.

Increasing diagnoses of paraneoplastic neurologic syndromes in the U.S. correlates to heightened awareness by physicians as well as greater testing availability, according to a population-based epidemiology study published in Neurology: Neuroimmunology & Neuroinflammation.

Healio Neurology’s five most-viewed stories in December highlight a study on increased sun exposure lowering children’s MS risk, FDA approval of a treatment for myasthenia gravis and research on a self-administered examination that may quickly identify mild cognitive impairment conversion to dementia.